Contact: Nicole Napoli, firstname.lastname@example.org, 202-375-6523
WASHINGTON (Sep 17, 2020) -
The American College of Cardiology’s ongoing COVID-19 response initiative is welcoming support from the Boehringer Ingelheim and Eli Lilly and Company Alliance to continue providing real-time clinical guidance on COVID-19. The comprehensive initiative includes a robust set of activities and events implemented by ACC to help cardiologists address critical patient needs and continue to deliver high-quality care.
People with existing cardiovascular disease are at high risk of lung damage and cardiovascular complications if they contract COVID-19. This is further complicated by an increased risk of developing co-morbid conditions associated with heart disease. As the pandemic progresses, many clinicians are looking for real-time guidance on managing care for these vulnerable patients, while minimizing risk to themselves and the entire cardiovascular care team.
The ACC has increasingly focused its COVID-19 response initiative on four broad areas of critical need, including key clinical/scientific guidance, optimizing cardiovascular care and operational considerations, clinician wellness, and disparities in care. This initiative, anchored by ACC’s COVID-19 hub, provides a platform for providing education and resources around these areas that clinicians can immediately put into practice as the pandemic evolves.
“The ACC is committed to transforming cardiovascular care and improving heart health, and today, that can’t be accomplished without addressing the impact the pandemic has had on our patients,” said ACC President Athena Poppas, MD, FACC. “Through this initiative, we are supporting members to answer pressing clinical questions, develop care delivery models and update the science for the health of our practices and our patients.”
Highlights of the programs and resources offered in ACC’s COVID-19 response initiative include:
- The Summer COVID-19 Education Series – A free weekly virtual meeting providing the health care community with actionable insights and solutions to address key clinical and operational concerns.
- Quick Tips for Fast Thinking - A video library featuring ACC thought leaders providing structured reviews of emerging science, perspectives from the frontline, and guidance on non-clinical issues and sharing best practices.
“Cardiology care teams need support in navigating the unique challenges brought on by COVID-19 to ensure that this high-risk patient community continues to receive the best possible care, guided by the latest science and recommendations,” said Mohamed Eid, MD, MPH, MHA, vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. “The Boehringer Ingelheim and Lilly Alliance is proud to partner with the ACC to deliver real-time education to ensure the continuity of high-quality care to people with cardiovascular disease.”
To access the ACC’s comprehensive tools and resources for clinicians and patients, visit the ACC’s COVID-19 Hub at www.acc.org/COVID19.
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.
About Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of around $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and is part of the Boehringer Ingelheim group of companies. In addition, there are Boehringer Ingelheim Animal Health in Duluth, GA and Boehringer Ingelheim Fremont, Inc. in Fremont, CA.
Boehringer Ingelheim is committed to improving lives and strengthening our communities. Please visit www.boehringer-ingelheim.us/csrto learn more about Corporate Social Responsibility initiatives.
For more information, please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us atwww.lilly.com and newsroom.lilly.com/social-channels.
Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centers on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need.